MicroRNAs: Crucial Regulators of Stress

Author(s): Rabih Roufayel, Seifedine kadry*

Journal Name: MicroRNA

Volume 9 , Issue 2 , 2020


Become EABM
Become Reviewer
Call for Editor
REVIEW ARTICLE

MicroRNAs: Crucial Regulators of Stress

Rabih Roufayel1, 2 and Seifedine Kadry3, *

1Department of Science, College of Engineering and Technology, American University of the Middle East, Egaila, Kuwait;
2Department of Molecular and Cellular Biology, University of Guelph, 50 Stone Road East, Guelph, Ontario, N1G 2W1, Canada;
3Department of Mathematics and Computer Science, Faculty of Science, Beirut Arab University, Beirut, Lebanon

Abstract: Background: Signaling pathways including gene silencing, cellular differentiation, homeostasis, development and apoptosis are regulated and controlled by a wide range of miRNAs.

Objective: Due to their potential binding sites in human-protein coding genes, many studies have also linked their altered expressions in various cancer types making them tumor suppressors agents.

Methods: Moreover, each miRNA is predicted to have many mRNA targets indicating their extensive regulatory role in cell survival and developmental processes. Nowadays, diagnosis of early cancer stage development is now dependent on variable miRNA expression levels as potential oncogenic biomarkers in validating and targeting microRNAs for cancer therapy.

Results: As the majority of miRNA, transcripts are derived from RNA polymerase II-directed transcription, stress response could result on a general reduction in the abundance of these transcripts. Over expression of various microRNAs have lead to B cell malignancy, potentiated KrasG12D-induced lung tumorigenesis, chronic lymphocytic leukemia, lymphoproliferative disease and autoimmunity.

Conclusion: Altered miRNA expressions could have a significant impact on the abundance of proteins, making them attractive candidates as biomarkers for cancer detection and important regulators of apoptosis.

Keyword: Apoptosis, cancer, miRNAs, regulators, stress, leukemia.


Article Information

Identifiers and Pagination:

Year: 2020
Volume: 9
Issue: 2
First Page: 93
Last Page: 100
Publisher Id: MIRNA-9-2-93
DOI: 10.2174/2211536608666190625120127

Article History:

Received Date: January 25, 2019
Revised Date: April 03, 2019
Accepted Date: May 21, 2019

* Address correspondence to this author at the Department of Mathematics and Computer Science, Faculty of Science, Beirut Arab University, Beirut, Lebanon; Tel: 009613700512; E-mail: s.kadry@bau.edu.lb

1. INTRODUCTION

1.1. Discovery of miRNAs and their Regulation of Gene Expression

MicroRNAs (miRNAs) have been shown to play a wide integral role in cellular processes by controlling mRNAs’ stability and translation of their target genes [1]. Less than 2% of the human genome is transcribed into mRNA transcripts and is regulated by the non-coding RNAs [2 - 4]. Developmental studies in the 1990s revealed the first endogenous ~22 nucleotide (nt) regulatory ribonucleic acids (RNAs) in C. elegans and demonstrated that diverse 3’ untranslated region (UTR) motifs mediated crucial modes of post-transcriptional repression of gene expression in Drosophila melanogaster [5, 6]. This posttranscriptional modification of gene expression is carried out by the action of a group of these single-stranded miRNAs. Many studies have adopted the essential tumor suppressing roles of miRNAs and their downregulated expression levels showed elevated progression and development in many cancer types including acute lymphoblastic leukemia and acute myeloid leukemia [7]. Aberrant miRNA expression and processing resulted in their deregulated expressions in a number of diseases. More than 60% of the human protein-coding genes have been encoded as potential binding sites for miRNAs indicating their massive regulatory roles in cell survival and developmental processes [8].

2. miRNA BIOGENESIS

miRNAs are defined as small, non-coding RNAs that repress the translation of target messenger RNAs (mRNAs) [9, 10]. Mature miRNAs function by the formation of hairpin transcripts that are processed into short RNAs that are associated with Argonaute (Ago) proteins and form the RNA-Induced Silencing Complex (RISC), a ribonucleoprotein complex mediating post-transcriptional gene silencing [9]. The RISC complex also guides complementary miRNAs to target mRNAs for degradation, destabilization, or translational inhibition by the Ago protein [9 - 11].

miRNA biogenesis starts with the transcription of miRNA genes by either RNA polymerase II/III into primary miRNA (pri-miRNA) transcripts [12, 13]. The long primary miRNA transcript is synthesized in the nucleus from non-coding DNA and processed by an RNAse enzyme named Drosha and the DGCR8 (DiGeorge Critical Region 8) protein, also known as Pasha, to a ~70 nt precursor miRNA (pre-miRNA). After nuclear processing, the pre-miRNA is exported to the cytoplasm by Exportin-5 (XPO5) in a complex with Ran-GTP [14]. It is in the cytoplasm where the miRNA is further processed by the RNAse enzyme Dicer to give rise to the mature ~22 nt miRNA. RISC, with its core Argonaute (Ago2) protein component, is the cytoplasmic effector of the miRNA pathway and binds to a single-stranded miRNA, guiding it to its target mRNAs [15]. A mature miRNA is able to regulate gene expression by either binding to the 3’UTR of its target mRNA (Fig. 1) causing translational inhibition or even its targeted destruction. Yet, the consequences for mRNA targets are very different: mRNA degradation results in irreversible removal from the transcriptome, whereas the level of mRNA targets can remain constant or even increase upon inhibition of translation.

Fig. (1). miRNA regulation of gene expression. miRNAs are generated as primary (pri-miRNA) transcripts by RNA polymerase II/III in the nucleus. After being processed by the endonucleases Drosha and Pasha, the stem-loop structure of the precursor miRNA (pre-miRNA) is exported out of the nucleus by Exportin-5 (XPO-5). The endonuclease Dicer releases the mature miRNA, which is then assembled into the RNA-induced silencing complex (RISC). The RISC directs its bound miRNA to partially complementary mRNA 3’ untranslated regions, resulting in inhibition of translation or targeted destruction of the mRNA [12 - 15].

3. REGULATION OF miRNA EXPRESSION

The questions related to what regulates miRNA is of major interest since these small RNA molecules are associated with many developmental and disease processes [16]. MiRNA expressions are encoded by genes, thereby, their expressions are regulated by various means including both the transcription regulation or processing [17, 18]. Another mode of regulation is linked to the nuclear export of pre-miRNA precursors or their localization to specific cytoplasmic compartments associated with the regulation of mRNAs’ stability and RNA interference [14].

The location of miRNA genes within the genome is also a major feature in terms of transcriptional regulation. Several miRNA genes are located within the non-coding regions of other host genes leading to the cotranscription with the genes that contain them that are involved in the same biological pathways [19]. Other miRNAs are found to be located in the intergenic regions, having an independent transcription site. Although all primary miRNA transcripts are transcribed by RNA polymerase II and initiated by promoters, many transcription factors are not fully understood. Several transcription factors such as tumor suppressor p53 have been liked with the regulation of many miRNAs that are involved in apoptotic regulation and cell proliferation including miR-23a, miR-21, miR-34, miR-145, miR-192 and miR-215, miR-17-92 [20 - 22].

Posttranscriptional modification of miRNA is an important feature that needs to be taken into consideration as well [23]. Pre-mRNA processing including packaging and alternative splicing is under the control of a nuclear RNA-binding protein HnRNP A1. It plays an important in miRNA production by inducing conformational changes in the pri-miRNA transcripts that enhance its processing by Drosha and the DGCR8 protein [14]. Many miRNAs are shown to be regulated by post-transcriptional modifications such as let-7 family in embryonic cells, lin28 in C. elegans and miR-18 in HeLa cells [24, 25]. In humans, both lin28 and let-7 manipulated expressions are considered as important biomarkers for cancer progression, stem cell aging and pluripotency. Moreover, transgenic mice with different genetic variation lin28-let7 expressions have shown significant changes in body size and delayed onset of puberty [26].

4. miRNA REGULATION OF THE STRESS RESPONSE

miRNAs are widely expressed and regulate essentially all signaling pathways, playing an important role in gene silencing and controlling a number of essential processes including cell proliferation, development, differentiation and apoptosis [7, 27, 28]. There are over 1000 human miRNAs currently identified in the miRNA database released October 10, 2010 (http://www.mirbase.org), even outnumbering kinases and phosphatases, indicating their extensive role in the regulation of cellular processes. Each miRNA is predicted to bind hundreds of target mRNAs, therefore a large portion of human genes are subject to miRNA regulation [29]. This binding morphology implies that the expression of the mRNA target is likely to be under the control of multiple miRNAs [30]. Consequently, nearly all developmental, physiological and disease-related processes appear to be regulated by miRNAs, at least to some degree [8]. Notably, miRNA processing defects may also enhance tumorigenesis [31]. Aberrant miRNA processing leads to altered expression of mature miRNAs, often contributing to the disease. Over 120 miRNA transcripts demonstrate differential expression in response to hyperthermia [32] and interestingly HSP70 has also been shown to influence miRNA processing [33]. At present, this mechanism is, however, not well understood.

Many reports have shown deregulation of miRNAs in certain cancer types while others provided important pro-apoptotic functions. A group of miRNAs including miR-330, Let-7 family and miR-15a/16 have been downregulated in several cancer types including prostate, colon, breast and prostate. These preliminary analyses can be used as promising biomarkers for anticancer therapy [34 - 37]. Reduced levels of mature miRNAs were also reported in various tumors primarily due to epigenetic silencing or alterations in biogenesis pathways [38]. Nowadays, the diagnosis of early cancer stage development is now dependent on variable miRNA expression levels as potential oncogenic biomarkers in validating and targeting microRNAs for cancer therapy. Overexpression of various microRNAs including miR-155, miR-21, miR-29 and miR-17~92 has led to B cell malignancy, potentiated KrasG12D-induced lung tumorigenesis, chronic lymphocytic leukemia and Lymphoproliferative disease and autoimmunity, respectively [39, 40].

Cell survival is directly related to miRNA regulations and not surprisingly their expression is often altered in a number of diseases including cancer [41]. The majority of miRNAs are transcribed as a part of a cluster and their overexpression is implicated in many diseases such as cancer and cardiac hypertrophy [42]. Some pro-survival miRNAs act as suppressors and inhibit the expression of pro-apoptotic regulators APAF1, caspase-7 and NOXA [21, 43, 44]. Stress-induced factors such as hyperthermia have shown to decrease miR-23a levels resulting in the overexpression of the pro-apoptotic protein NOXA and leading to apoptosis [21]. Another study showed that the decrease in the abundance of miR-23a is due to CDK5 inhibition and this phenomenon could be reverted by the overexpression of the molecular chaperon HSP70 in stressed cells [45]. Hyperthermia has been shown to alter the expression profile of numerous miRNAs [21, 43, 45]. Screening of miRNA microarrays revealed that 123 different miRNA transcripts were affected by exposure of cells to hyperthermia with both increased and decreased expression of various miRNAs [21, 32, 43]. Whether altered miRNA expression contributes to heat-induced apoptosis is not known.

5. miRNA MODULATION BY P53

Recent reports show that misexpression of miRNAs, whether elevated or reduced, is seen in all types of cancer [7, 9]. As a protein that senses environmental stress and modulates the level of miRNAs, the tumor suppressor p53 regulates the expression of specific miRNAs at two different levels: transcription and processing. Upon DNA damage, p53 induces the transcription of some miRNAs that together promote tumorigenesis by blocking p53, thus preventing cell cycle arrest or apoptosis [46]. These miRNAs can be classified as oncogenic miRNAs. In addition, p53 enhances the processing of certain pri-miRNAs in cancer cells by associating with DDX5, a cofactor of Drosha [47]. Overexpression of these miRNAs can act as tumor suppressors, not necessarily by inhibiting cell growth, but by preventing the progression of cancer [9]. Interestingly, most p53 mutations found in cancers are located in a domain that is required for both the miRNA processing function and transcriptional activity [47]. Therefore, loss of p53 function in transcription and miRNA processing might contribute to tumor progression.

In response to the environmental stress, p53 modulates a number of specific miRNAs at their transcription and processing level. Many cancers contain p53 mutations located in a domain that is required for miRNA processing and its transcriptional activity [47]. Therefore, loss of p53 function could contribute to tumor progression by preventing stress-induced miRNA transcription and processing. Due to their overexpression in several human cancers, these miRNAs have been implicated as oncomirs, acting as tumor suppressors by preventing cancer progression [9].

6. miRNA REGULATION OF APOPTOTIC PROTEINS

Numerous studies have uncovered highly specific miRNA profiles during development, tumorigenesis and apoptosis [41, 48]. It is currently undisputed that miRNAs function as important regulators of apoptosis. Recent studies show that miRNAs can regulate the expression of key apoptotic regulators including the Bcl-2 family proteins. Zhang and colleagues found that miR-221 and miR-222 directly target PUMA mRNA translation in various types of cancer cells [17]. Many regulators such as miR-15, miR-16, and miR-34a were also documented to downregulate Bcl-2 in Chronic Lymphocytic Leukemia (CLL) [27, 49, 50]. Additionally, RNA interference (RNAi) mechanisms have been shown to regulate apoptosis directly by targeting these miRNAs and ultimately altering the expression of PUMA in glioblastoma, A549 lung and MCF-7 breast cancer cell lines (human breast cancer cell line with estrogen, progesterone and glucocorticoid receptors) [51]. A knockout of miR-221/miR-222 results in restoration of the pro-apoptotic PUMA protein and its activity inducing cancer cell apoptosis and inhibition of tumor growth in these cells (Fig. 2). miR-221 and miR-222 are only a few of the miRNAs shown to target and alter the expression of PUMA, and may, therefore, be potential therapeutic targets in the treatment of certain types of cancers [51]. Alternatively, Ouyang and colleagues found miR-29a to target PUMA mRNA when studying forebrain ischemia [52]. Another very recent study on the liver carcinoma cell line, HepG2, has raised the possibility that miR-483-3p modulates PUMA and that its induced expression can protect cells from apoptosis [53]. miR-BART5, an Epstein-Barr Virus (EBV) encoded miRNA is another miRNA that has been shown to have anti-apoptotic activity targeting PUMA expression in Nasopharyngeal Carcinoma (NPC) and in EBV-associated gastric carcinoma latently infected with EBV to protect these cells from apoptosis. Interestingly, this was the first evidence that some viruses are able to modulate cellular apoptosis through miRNAs [54]. Moreover, overexpression of miR-24-2 impairs the pro-survival of Bcl-2 by binding to its 3’UTR and activated apoptotic pathways in the Human Embryonic Kidney (HEK 293T) and breast cancer (MCF7) cells [55]. Transcribed as part of the miR-23a~27a~24-2 cluster, miR-23a is deregulated in several diseases including cancer where expression is elevated [42, 56]. This cluster has been found to be amplified in a mouse model of colon cancer and the elevated miR-23a expression was shown to promote the transition of indolent adenomas to invasive colorectal cancers [57]. Elevated expression of miR-23a was also documented in human colorectal cancers and colon cancer cell lines. miR-23a has been shown to target APAF1 (Chen et al., 2014), Caspase-7 (CASP7) [44], and NOXA [21] and together with our finding that it also targets NOXA, it reveals that this miRNA coordinately antagonizes the expression of multiple apoptotic regulators and therefore its down-regulation during proteotoxic stress ensures effective apoptotic pathway activation (Table 1). Because a large number of miRNAs contribute to the development of cancer and other diseases, the discovery of miRNA pathways has opened up a novel therapeutic approach for the treatment and these findings highlight the importance of miRNAs as promising therapeutic molecules.

Fig. (2). Diagram showing a mechanism of cellular apoptosis induction by miRNAs. Downregulation of the anti-apoptotic protein BCL2, miR-23a, miR-24-2, miR-15a/16 and miR-221/miR-222 reduce mitochondrial membrane potential and cause release of apoptotic molecule cytochrome c into the cytosol. Cytosolic cytochrome c leads to activation of a caspase cascade and ultimately results in apoptosis [21, 22, 34, 35, 51].

7. THERAPEUTIC ROLES OF miRNAs

Evasion of apoptosis is both a hallmark of cancer and is involved in tumorigenesis and drug resistance. Overcoming chemotherapeutic drug resistance remains a key challenge in the fight against cancer. This drug resistance may be in large part due to resistance to apoptosis. Where apoptosis can be effectively induced, dramatic clinical responses are often seen [58]. This reinforces the basic concept that achieving efficient apoptosis is essential for optimizing therapeutic responses and therefore the clinical outcome.

Recently miRNAs have been shown to be important in regulating apoptotic proteins and therefore cell death. The field of miRNAs based pharmacogenomics is still relatively new but given their involvement in the regulation of apoptosis and the understanding that most chemotherapeutic drugs kill cells by this mechanism, core apoptosis pathway-targeting miRNAs have good potential as predictors of anti-cancer drug efficacy [41]. This, along with the abundance and wide range of activity of miRNAs, makes them attractive candidates as biomarkers for cancer. In addition, the modulation of miRNA expression with miRNA mimetics or antagomirs may be a possible therapeutic avenue [28]. One advantage of using miRNAs as therapeutic targets is that they often regulate multiple mRNA targets that belong to the same signaling pathway or protein complexes at the same time [59, 60]. The key is to identify which miRNAs and which targets are involved in each particular disease. There are ongoing efforts to deliver miRNA mimics or perfectly complementary antagomir inhibitors to increase or decrease, respectively, the levels of specific miRNAs in vivo. In cases where a specific miRNA-mRNA target interaction should be modulated, short oligonucleotides termed as “target protectors” have been successfully applied in mammalian cells [61]. The idea of a target protector is that a single-strand oligonucleotide could specifically interfere with a single target while leaving the regulation of the other targets of the same miRNA unaffected. Ultimately, this avenue of research will lead to better understanding and treatment of diseases in which miRNAs mediate the modulation of mRNA expression. Once better understood, the expression of the miRNAs can be altered effectively to restore the expression of the target mRNA and protein.

Table 1. Validated miRNAs targeting pro- or anti-apoptotic proteins.

Anti-Apoptotic Pro-Apoptotic
NOXA and PUMA Mcl-1 Bcl-2 BCL-xL Bcl-w
miR-149-5p
miR-23a
miR-23b
miR-192
miR-125b
miR-155
miR-194
miR-215
miR-34a,b,c
miR-29
miR-30
miR-101
miR-125b
miR-133a
miR-133b
miR-153
miR-181
miR-193a
miR-302b
miR-320
miR-512
miR-15/16
miR-24
miR-34a [98]
miR-125b
miR-153
miR-155
miR-195 miR-204
miR-206
miR-365
miR-497
miR-1290
miR-15a/16
miR-221
miR-222
miR-23a
miR-24-2
Let-7c/g
miR-133a
miR-326
miR-377
miR-491
miR-608
Let-7a-3p
miR-107
miR-122
miR-125b
miR-133b
miR-203
miR-335

The importance of miRNA regulatory activities in multiple apoptotic pathways leads us to overcome many stress challenges by delivering these molecules in clinical implementations. Misregulation of miRNAs was observed in multiple cancer development situations accompanied by the inhibition of cellular survival and the activation of apoptotic pathways. Recent clinical trials used miRNAs that are potential biomarkers for patient diagnosis, stratification and drug treatments for therapeutical agents in cancer [62]. Anti-apoptotic Bcl-2 genes were downregulated upon the overexpression of miR-15, miR-16, and let-7, leading to the activation of cellular apoptotic pathways in cancer cells [27]. Another study demonstrated that Bcl protein was a downstream target for a group of microRNAs including miR-24-2, miR-195 and miR-365. Overexpression of these microRNAs led to induced apoptosis by directly inhibiting Bcl protein in a clinical breast cancer treatment [63]. Another clinical treatment used miR-34a mimic as a potential therapeutic strategy for blocking tumor cell migration in liver cancer patients [64].

CONCLUSION

The critical role that miRNAs play in the regulation of stress responses has only recently gained significant attention [65]. Their roles in apoptosis and tumorigenesis are well-documented and not surprisingly many apoptotic regulators including Bcl-2 family members NOXA, PUMA and caspases are regulated by miRNAs that in many cases have altered patterns of expression in several types of cancer such as lung, colon, breast and prostate cancer, and are therefore considered to be promising targets for anticancer therapy. There are only a few reports on miRNA expression in heat-stressed cells [66]. The recently discovered role of miRNAs as regulators of gene expression opened up several new areas of research and suggested that these can be used as important biomarkers. In general, the expression of some miRNAs was found to be enhanced while others’ expressions reduced in studies using both cell cultures and whole animals [67 - 69]. Studies indicate that directly targeting the apoptotic machinery through the manipulation of miRNA expression may offer a new hope for improved therapy for cancer and other autoimmune and infectious diseases. Cell lines that stably express the miRNAs under study here will allow the examination of their role in the heat-induced regulation of apoptotic protein expression and also other regulators of apoptosis that are implicated in the process of controlling. More importantly, stably transfected shRNA knockdown cells can be created to abolish miRNA expression with the hope of restoring apoptotic protein expression under conditions of cellular stress.

CONSENT FOR PUBLICATION

Not applicable.

FUNDING

This review was supported by American University of the Middle East, Egaila, Kuwait.

CONFLICT OF INTEREST

The authors declare no conflict of interest, financial or otherwise.

ACKNOWLEDGEMENTS

Declared none.

REFERENCES

[1]
Jonas S, Izaurralde E. Towards a molecular understanding of microRNA-mediated gene silencing. Nat Rev Genet 2015; 16(7): 421-33.
[http://dx.doi.org/10.1038/nrg3965] [PMID: 26077373]
[2]
Iyer MK, Niknafs YS, Malik R, et al. The landscape of long noncoding RNAs in the human transcriptome. Nat Genet 2015; 47(3): 199-208.
[http://dx.doi.org/10.1038/ng.3192] [PMID: 25599403]
[3]
Consortium F. Finishing the euchromatic sequence of the human genome. Nature 2004; 431(7011): 931-45.
[http://dx.doi.org/10.1038/nature03001] [PMID: 15496913]
[4]
Frith MC, Pheasant M, Mattick JS. The amazing complexity of the human transcriptome. Eur J Hum Genet 2005; 13(8): 894-7.
[http://dx.doi.org/10.1038/sj.ejhg.5201459] [PMID: 15970949]
[5]
Lai EC, Burks C, Posakony JW. The K box, a conserved 3′ UTR sequence motif, negatively regulates accumulation of enhancer of split complex transcripts. Development 1998; 125(20): 4077-88.
[PMID: 9735368]
[6]
Reinhart BJ, Slack FJ, Basson M, et al. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature 2000; 403(6772): 901-6.
[http://dx.doi.org/10.1038/35002607] [PMID: 10706289]
[7]
Wang Y, Li Z, He C, et al. MicroRNAs expression signatures are associated with lineage and survival in acute leukemias. Blood Cells Mol Dis 2010; 44(3): 191-7.
[http://dx.doi.org/10.1016/j.bcmd.2009.12.010] [PMID: 20110180]
[8]
Flynt AS, Lai EC. Biological principles of microRNA-mediated regulation: shared themes amid diversity. Nat Rev Genet 2008; 9(11): 831-42.
[http://dx.doi.org/10.1038/nrg2455] [PMID: 18852696]
[9]
Hammond SM. MicroRNA therapeutics: a new niche for antisense nucleic acids. Trends Mol Med 2006; 12(3): 99-101.
[http://dx.doi.org/10.1016/j.molmed.2006.01.004] [PMID: 16473043]
[10]
Fabian MR, Sonenberg N, Filipowicz W. Regulation of mRNA translation and stability by microRNAs. Annu Rev Biochem 2010; 79: 351-79.
[http://dx.doi.org/10.1146/annurev-biochem-060308-103103] [PMID: 20533884]
[11]
Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T. Identification of novel genes coding for small expressed RNAs. Science 2001; 294(5543): 853-8.
[http://dx.doi.org/10.1126/science.1064921] [PMID: 11679670]
[12]
Lee Y, Kim M, Han J, et al. MicroRNA genes are transcribed by RNA polymerase II. EMBO J 2004; 23(20): 4051-60.
[http://dx.doi.org/10.1038/sj.emboj.7600385] [PMID: 15372072]
[13]
Borchert GM, Lanier W, Davidson BL. RNA polymerase III transcribes human microRNAs. Nat Struct Mol Biol 2006; 13(12): 1097-101.
[http://dx.doi.org/10.1038/nsmb1167] [PMID: 17099701]
[14]
Yi R, Qin Y, Macara IG, Cullen BR. Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Genes Dev 2003; 17(24): 3011-6.
[http://dx.doi.org/10.1101/gad.1158803] [PMID: 14681208]
[15]
MacRae IJ, Ma E, Zhou M, Robinson CV, Doudna JA. In vitro reconstitution of the human RISC-loading complex. Proc Natl Acad Sci USA 2008; 105(2): 512-7.
[http://dx.doi.org/10.1073/pnas.0710869105] [PMID: 18178619]
[16]
Guo Y, Sun J, Lai D. Role of microRNAs in premature ovarian insufficiency. Reprod Biol Endocrinol 2017; 15(1): 38.
[http://dx.doi.org/10.1186/s12958-017-0256-3] [PMID: 28499456]
[17]
Zhang X, Zeng Y. Regulation of mammalian microRNA expression. J Cardiovasc Transl Res 2010; 3(3): 197-203.
[http://dx.doi.org/10.1007/s12265-010-9166-x] [PMID: 20560040]
[18]
Hu J, Zhai C, Hu J, et al. miR-23a inhibited IL-17-mediated proinflammatory mediators expression via targeting IKKα in articular chondrocytes. Int Immunopharmacol 2017; 43: 1-6.
[http://dx.doi.org/10.1016/j.intimp.2016.11.031] [PMID: 27936459]
[19]
Golan D, Levy C, Friedman B, Shomron N. Biased hosting of intronic microRNA genes. Bioinformatics 2010; 26(8): 992-5.
[http://dx.doi.org/10.1093/bioinformatics/btq077] [PMID: 20185406]
[20]
Feng Z, Zhang C, Wu R, Hu W. Tumor suppressor p53 meets microRNAs. J Mol Cell Biol 2011; 3(1): 44-50.
[http://dx.doi.org/10.1093/jmcb/mjq040] [PMID: 21278451]
[21]
Roufayel R, Johnston DS, Mosser DD. The elimination of miR-23a in heat-stressed cells promotes NOXA-induced cell death and is prevented by HSP70. Cell Death Dis 2014; 5e: 1546.
[http://dx.doi.org/10.1038/cddis.2014.484] [PMID: 25429623]
[22]
Han H, Qu G, Han C, et al. miR-34a, miR-21 and miR-23a as potential biomarkers for coronary artery disease: a pilot microarray study and confirmation in a 32 patient cohort. Exp Mol Med 2015; 47(2) e138
[http://dx.doi.org/10.1038/emm.2014.81] [PMID: 25656948]
[23]
Obernosterer G, Leuschner PJ, Alenius M, Martinez J. Post-transcriptional regulation of microRNA expression. RNA 2006; 12(7): 1161-7.
[http://dx.doi.org/10.1261/rna.2322506] [PMID: 16738409]
[24]
Viswanathan SR, Daley GQ, Gregory RI. Selective blockade of microRNA processing by Lin28. Science 2008; 320(5872): 97-100.
[http://dx.doi.org/10.1126/science.1154040] [PMID: 18292307]
[25]
Guil S, Cáceres JF. The multifunctional RNA-binding protein hnRNP A1 is required for processing of miR-18a. Nat Struct Mol Biol 2007; 14(7): 591-6.
[http://dx.doi.org/10.1038/nsmb1250] [PMID: 17558416]
[26]
Zhu H, Shah S, Shyh-Chang N, et al. Lin28a transgenic mice manifest size and puberty phenotypes identified in human genetic association studies. Nat Genet 2010; 42(7): 626-30.
[http://dx.doi.org/10.1038/ng.593] [PMID: 20512147]
[27]
Cimmino A, Calin GA, Fabbri M, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA 2005; 102(39): 13944-9.
[http://dx.doi.org/10.1073/pnas.0506654102] [PMID: 16166262]
[28]
Garzon R, Marcucci G, Croce CM. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov 2010; 9(10): 775-89.
[http://dx.doi.org/10.1038/nrd3179] [PMID: 20885409]
[29]
Friedman RC, Farh KKH, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009; 19(1): 92-105.
[http://dx.doi.org/10.1101/gr.082701.108] [PMID: 18955434]
[30]
Krek A, Grün D, Poy MN, et al. Combinatorial microRNA target predictions. Nat Genet 2005; 37(5): 495-500.
[http://dx.doi.org/10.1038/ng1536] [PMID: 15806104]
[31]
Kumar MS, Lu J, Mercer KL, Golub TR, Jacks T. Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat Genet 2007; 39(5): 673-7.
[http://dx.doi.org/10.1038/ng2003] [PMID: 17401365]
[32]
Wilmink GJ, Roth CL, Ibey BL, et al. Identification of microRNAs associated with hyperthermia-induced cellular stress response. Cell Stress Chaperones 2010; 15(6): 1027-38.
[http://dx.doi.org/10.1007/s12192-010-0189-7] [PMID: 20352393]
[33]
Iwasaki S, Kobayashi M, Yoda M, et al. Hsc70/Hsp90 chaperone machinery mediates ATP-dependent RISC loading of small RNA duplexes. Mol Cell 2010; 39(2): 292-9.
[http://dx.doi.org/10.1016/j.molcel.2010.05.015] [PMID: 20605501]
[34]
Bandi N, Zbinden S, Gugger M, et al. miR-15a and miR-16 are implicated in cell cycle regulation in a Rb-dependent manner and are frequently deleted or down-regulated in non-small cell lung cancer. Cancer Res 2009; 69(13): 5553-9.
[http://dx.doi.org/10.1158/0008-5472.CAN-08-4277] [PMID: 19549910]
[35]
Takamizawa J, Konishi H, Yanagisawa K, et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 2004; 64(11): 3753-6.
[http://dx.doi.org/10.1158/0008-5472.CAN-04-0637] [PMID: 15172979]
[36]
Mott JL, Kobayashi S, Bronk SF, Gores GJ. mir-29 regulates Mcl-1 protein expression and apoptosis. Oncogene 2007; 26(42): 6133-40.
[http://dx.doi.org/10.1038/sj.onc.1210436] [PMID: 17404574]
[37]
Hayashita Y, Osada H, Tatematsu Y, et al. A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res 2005; 65(21): 9628-32.
[http://dx.doi.org/10.1158/0008-5472.CAN-05-2352] [PMID: 16266980]
[38]
Chang TC, Yu D, Lee YS, et al. Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet 2008; 40(1): 43-50.
[http://dx.doi.org/10.1038/ng.2007.30] [PMID: 18066065]
[39]
Kasinski AL, Slack FJ. Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat Rev Cancer 2011; 11(12): 849-64.
[http://dx.doi.org/10.1038/nrc3166] [PMID: 22113163]
[40]
Iorio MV, Croce CM. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med 2012; 4(3): 143-59.
[http://dx.doi.org/10.1002/emmm.201100209] [PMID: 22351564]
[41]
Lima RT, Busacca S, Almeida GM, Gaudino G, Fennell DA, Vasconcelos MH. MicroRNA regulation of core apoptosis pathways in cancer. Eur J Cancer 2011; 47(2): 163-74.
[http://dx.doi.org/10.1016/j.ejca.2010.11.005] [PMID: 21145728]
[42]
Chhabra R, Dubey R, Saini N. Cooperative and individualistic functions of the microRNAs in the miR-23a~27a~24-2 cluster and its implication in human diseases. Mol Cancer 2010; 9: 232.
[http://dx.doi.org/10.1186/1476-4598-9-232] [PMID: 20815877]
[43]
Chen Q, Xu J, Li L, et al. MicroRNA-23a/b and microRNA-27a/b suppress Apaf-1 protein and alleviate hypoxia-induced neuronal apoptosis. Cell Death Dis 2014; 5 e1132
[http://dx.doi.org/10.1038/cddis.2014.92] [PMID: 24651435]
[44]
Mao J, Lv Z, Zhuang Y. MicroRNA-23a is involved in tumor necrosis factor-α induced apoptosis in mesenchymal stem cells and myocardial infarction. Exp Mol Pathol 2014; 97(1): 23-30.
[http://dx.doi.org/10.1016/j.yexmp.2013.11.005] [PMID: 4269648]
[45]
Morey TM, Roufayel R, Johnston DS, Fletcher AS, Mosser DD. Heat shock inhibition of CDK5 increases NOXA levels through miR-23a repression. J Biol Chem 2015; 290(18): 11443-54.
[http://dx.doi.org/10.1074/jbc.M114.625988] [PMID: 25829494]
[46]
Hermeking H, Lengauer C, Polyak K, et al. 14-3-3sigma is a p53-regulated inhibitor of G2/M progression. Mol Cell 1997; 1(1): 3-11.
[http://dx.doi.org/10.1016/S1097-2765(00)80002-7] [PMID: 9659898]
[47]
Suzuki HI, Yamagata K, Sugimoto K, Iwamoto T, Kato S, Miyazono K. Modulation of microRNA processing by p53. Nature 2009; 460(7254): 529-33.
[http://dx.doi.org/10.1038/nature08199] [PMID: 19626115]
[48]
Di Leva G, Garofalo M, Croce CM. MicroRNAs in cancer. Annu Rev Pathol 2014; 9: 287-314.
[http://dx.doi.org/10.1146/annurev-pathol-012513-104715] [PMID: 24079833]
[49]
Xia L, Zhang D, Du R, et al. miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int J Cancer 2008; 123(2): 372-9.
[http://dx.doi.org/10.1002/ijc.23501] [PMID: 18449891]
[50]
Kojima K, Fujita Y, Nozawa Y, Deguchi T, Ito M. MiR-34a attenuates paclitaxel-resistance of hormone-refractory prostate cancer PC3 cells through direct and indirect mechanisms. Prostate 2010; 70(14): 1501-12.
[http://dx.doi.org/10.1002/pros.21185] [PMID: 20687223]
[51]
Zhang C, Zhang J, Zhang A, et al. PUMA is a novel target of miR-221/222 in human epithelial cancers. Int J Oncol 2010; 37(6): 1621-6.
[PMID: 21042732]
[52]
Ouyang YB, Xu L, Lu Y, et al. Astrocyte-enriched miR-29a targets PUMA and reduces neuronal vulnerability to forebrain ischemia. Glia 2013; 61(11): 1784-94.
[http://dx.doi.org/10.1002/glia.22556] [PMID: 24038396]
[53]
Veronese A, Lupini L, Consiglio J, et al. Oncogenic role of miR-483-3p at the IGF2/483 locus. Cancer Res 2010; 70(8): 3140-9.
[http://dx.doi.org/10.1158/0008-5472.CAN-09-4456] [PMID: 20388800]
[54]
Yin C, Wang X, Kukreja RC. Endogenous microRNAs induced by heat-shock reduce myocardial infarction following ischemia-reperfusion in mice. FEBS Lett 2008; 582(30): 4137-42.
[http://dx.doi.org/10.1016/j.febslet.2008.11.014] [PMID: 19041309]
[55]
Srivastava N, Manvati S, Srivastava A, et al. miR-24-2 controls H2AFX expression regardless of gene copy number alteration and induces apoptosis by targeting antiapoptotic gene BCL-2: a potential for therapeutic intervention. Breast Cancer Res 2011; 13(2): R39.
[http://dx.doi.org/10.1186/bcr2861] [PMID: 21463514]
[56]
Musto A, Navarra A, Vocca A, et al. miR-23a, miR-24 and miR-27a protect differentiating ESCs from BMP4-induced apoptosis. Cell Death Differ 2015; 22(6): 1047-57.
[http://dx.doi.org/10.1038/cdd.2014.198] [PMID: 25476774]
[57]
Zhang L, Li J, Xu W. A review of the role of PUMA, Noxa and Bim in the tumorigenesis, therapy and drug resistance of chronic lymphocytic leukemia. Nature 2012; 1: 7.
[PMID: 23175245]
[58]
Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350(21): 2129-39.
[http://dx.doi.org/10.1056/NEJMoa040938] [PMID: 15118073]
[59]
Ebert MS, Sharp PA. MicroRNA sponges: progress and possibilities. RNA 2010; 16(11): 2043-50.
[http://dx.doi.org/10.1261/rna.2414110] [PMID: 20855538]
[60]
Tsang JS, Ebert MS, van Oudenaarden A. Genome-wide dissection of microRNA functions and cotargeting networks using gene set signatures. Mol Cell 2010; 38(1): 140-53.
[http://dx.doi.org/10.1016/j.molcel.2010.03.007] [PMID: 20385095]
[61]
Choi WY, Giraldez AJ, Schier AF. Target protectors reveal dampening and balancing of nodal agonist and antagonist by miR-430. Science 2007; 318(5848): 271-4.
[http://dx.doi.org/10.1126/science.1147535] [PMID: 17761850]
[62]
Agostini M, Knight RA. miR-34: from bench to bedside. Oncotarget 2014; 5(4): 872-81.
[63]
Bouchie A. First microRNA mimic enters clinic. Nat Biotechnol 2013; 31(7): 577.
[http://dx.doi.org/10.1038/nbt0713-577] [PMID: 23839128]
[64]
Daige CL, Wiggins JF, Priddy L, Nelligan-Davis T, Zhao J, Brown D. Systemic delivery of a miR34a mimic as a potential therapeutic for liver cancer. Mol Cancer Ther 2014; 13(10): 2352-60.
[http://dx.doi.org/10.1158/1535-7163.MCT-14-0209] [PMID: 25053820]
[65]
Leung AK, Sharp PA. MicroRNA functions in stress responses. Mol Cell 2010; 40(2): 205-15.
[http://dx.doi.org/10.1016/j.molcel.2010.09.027] [PMID: 20965416]
[66]
Place RF, Noonan EJ. Non-coding RNAs turn up the heat: an emerging layer of novel regulators in the mammalian heat shock response. Cell Stress Chaperones 2014; 19(2): 159-72.
[http://dx.doi.org/10.1007/s12192-013-0456-5] [PMID: 24002685]
[67]
Liu X, Sempere LF, Ouyang H, et al. MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors. J Clin Invest 2010; 120(4): 1298-309.
[http://dx.doi.org/10.1172/JCI39566] [PMID: 20237410]
[68]
Oshlag JZ, Devasthanam AS, Tomasi TB. Mild hyperthermia enhances the expression and induces oscillations in the Dicer protein. Int J Hyperthermia 2013; 29(1): 51-61.
[http://dx.doi.org/10.3109/02656736.2012.753471] [PMID: 23311378]
[69]
Yu J, Liu F, Yin P, et al. Integrating miRNA and mRNA expression profiles in response to heat stress-induced injury in rat small intestine. Funct Integr Genomics 2011; 11(2): 203-13.
[http://dx.doi.org/10.1007/s10142-010-0198-8] [PMID: 21057845]